Spectral AI, Inc. MDAI

Spectral AI, Inc. announced that its DeepView multispectral imaging system will be featured in a presentation at the ACS Clinical Congress 2026 in Washington, DC (Sept 26–29). Led by Dr. James H. Holmes IV, the study covers artificial intelligence training and validation for evaluating burn wounds, with contributions from burn centers and researchers including Dr. J. Michael DiMaio, Spectral AI's chairman. The DeepView System is FDA De Novo cleared (May 2026) and UKCA authorized (Feb 2024). It combines multispectral imaging with proprietary AI to predict wound healing and flag areas unlikely to heal within 21 days, enabling earlier intervention. Image capture takes 0.2 seconds; AI classification takes 20–25 seconds; trained on a database of over 340 billion burn-wound pixels. Spectral AI seeks broader surgeon adoption beyond burn centers and notes BARDA contract via its subsidiary Spectral MD. FDA clearance and BARDA backing, plus broad ACS exposure, could moderately lift adoption and investor sentiment.

Spectral AI (MDAI) remains in a holding period after regulatory approval but before generating initial sales revenue. Post-approval waiting period may influence near-term revenue expectations without immediate sales.

Spectral AI, Inc. held its Q2 2026 earnings call, covering financial results, operational updates and forward guidance for the company. Quarterly earnings releases supply key financial data that can moderately shift near-term stock valuation and sentiment.

Spectral AI reported Q2 financial results and operational updates during its earnings call, outlining revenue figures, R&D progress on AI wound assessment tools, and cash position guidance. Quarterly earnings provide updated financial metrics and forward guidance that can shift near-term investor views but rarely redefine long-term strategy alone.

Spectral AI, Inc. (MDAI) announced its financial results for the second quarter of 2026. Quarterly earnings releases can move stock prices and affect near-term sentiment for small-cap companies.

Spectral AI appoints Darcy Bajko Chief Commercial Officer to lead global sales launch of its FDA-cleared DeepView system for burn indication. New CCO appointment directly tied to commercial rollout of cleared flagship product positions company for accelerated revenue generation and market expansion.

Spectral AI receives FDA clearance for its DeepView system, driving a sharp increase in company valuation. FDA clearance for DeepView constitutes a major regulatory milestone that can accelerate commercialization and materially lift investor sentiment.

Spectral AI receives FDA De Novo Clearance for DeepView System for burn indication. FDA clearance enables commercial launch of core DeepView product.

Spectral AI, Inc. (MDAI) released its first quarter 2026 financial results. Quarterly earnings results directly impact investor sentiment, stock volatility, and future market performance for MDAI.

Spectral AI Inc (MDAI) detailed strategic advances in Q1 2026 earnings call amid financial challenges. Strategic advances in Q1 2026 earnings call signal major shifts in MDAI's trajectory despite financial hurdles.

Spectral AI, Inc. (MDAI) announced first quarter 2026 financial results. Quarterly financial results announcements typically drive significant shifts in investor sentiment and stock trajectory.

Spectral AI's Q1 earnings call highlighted key financial results, operational updates, and future outlook for the AI-driven wound care company. Q1 earnings highlights provide moderate insight into financial health and strategy, influencing investor sentiment without transformative shifts.

Spectral AI showcased its DeepView® System at the 2026 American Burn Association Annual Meeting. Showcasing DeepView at the American Burn Association Annual Meeting provides moderate visibility and validation in burn care, potentially influencing product adoption and competitive positioning.

Spectral AI, Inc. (MDAI) appoints David McGuire, CPA, as Chief Financial Officer. Appointing a CPA as CFO bolsters financial leadership, moderately influencing oversight, reporting, and investor confidence.

Spectral AI, Inc. (MDAI) DeepView system awarded $32 million contract from BARDA to advance AI-powered wound imaging for clinical validation and commercialization. $32 million BARDA award delivers non-dilutive funding and regulatory validation, positioning DeepView to redefine wound care and elevate MDAI's competitive standing.

Spectral AI, Inc. (MDAI) announces its DeepView system awarded $32 million from BARDA to advance wound care imaging technology. $32 million BARDA award delivers major funding and regulatory validation for DeepView, poised to accelerate Spectral AI's growth and market performance.

Spectral AI, Inc. (MDAI) Q4 2025 earnings call summary covers quarterly financial results, operational highlights, and future guidance. Q4 earnings call summary discloses financial performance and strategic outlook significantly affecting MDAI's market trajectory.

Spectral AI (MDAI) released Q4 2025 earnings call transcript detailing financial results, operational updates, and forward guidance. Q4 earnings transcript provides critical financial data and strategic insights likely to influence MDAI stock performance and trajectory.

Spectral AI Inc (MDAI) Q4 2025 earnings call highlights navigating operational challenges while seizing growth opportunities. Earnings call highlights reveal strategic responses to challenges and opportunities, significantly impacting financial outlook and market sentiment.

Spectral AI, Inc. (MDAI) announced fourth quarter and full-year 2025 financial results and introduced revenue guidance for 2026. Financial results and 2026 revenue guidance disclosure will significantly sway investor sentiment and stock trajectory.

Spectral AI, Inc. (MDAI) released Q4 earnings call highlights, detailing financial results, revenue growth, product pipeline updates, and optimistic 2024 guidance amid advancements in AI-driven wound care technology. Q4 earnings highlights indicate solid financial progress and forward guidance with moderate influence on market performance and investor confidence.

Spectral AI, Inc. (MDAI) received $31.7 million in BARDA funding to accelerate development of its DeepView® System for wound care. $31.7 million BARDA funding profoundly accelerates DeepView® development, validating technology and redefining Spectral AI's competitive edge and growth trajectory.

Spectral AI, Inc. has appointed Vincent S. Capone as its new Chief Executive Officer. Capone brings extensive experience in the technology and healthcare sectors, having previously held leadership roles at various companies. His appointment is expected to drive the company's strategic vision and enhance its market position. The appointment of a new CEO with significant experience is likely to influence the company's strategic direction and market performance.

Spectral AI, Inc. (MDAI) is poised for significant developments as it approaches mid-year authorization. The company is preparing to launch its innovative solutions, which are expected to enhance its market position and operational capabilities. Investors are closely monitoring these advancements, anticipating a positive impact on the company's trajectory. Mid-year authorization and product launches are likely to significantly influence MDAI's market performance and investor sentiment.

An intrinsic calculation indicates that Spectral AI, Inc. (NASDAQ:MDAI) is currently undervalued by approximately 25%. This assessment suggests potential for growth in the company's market performance, highlighting a favorable investment opportunity for stakeholders. The intrinsic valuation suggests significant potential for growth and investor interest.

Spectral AI, Inc. showcased its DeepView™ System at the 2025 US Burn Conferences, highlighting its innovative technology designed to enhance burn care and treatment. The system aims to improve patient outcomes through advanced imaging and analysis capabilities, positioning the company as a leader in the medical technology sector focused on burn injuries. The introduction of the DeepView™ System at a prominent conference indicates a significant strategic move that could enhance market positioning and investor sentiment.

Spectral AI, Inc. (MDAI) reported its Q3 2025 earnings, highlighting challenges faced in the current market environment while also outlining strategies to seize emerging opportunities. The company emphasized its commitment to innovation and adapting to changing conditions, aiming to enhance its competitive positioning. Key financial metrics were discussed, reflecting the impact of recent market dynamics on performance. Management expressed optimism about future growth prospects despite ongoing hurdles. Moderate influence on financial performance and competitive positioning is expected due to the outlined strategies and market challenges.

Spectral AI, Inc. (MDAI) reported its Q3 2025 earnings, highlighting significant advancements in its AI-driven solutions for medical imaging. The company showcased improved revenue figures and a strategic focus on expanding its product offerings. Management emphasized ongoing investments in research and development to enhance competitive positioning. The earnings call also addressed market challenges and opportunities, with a positive outlook for future growth driven by technological innovations and partnerships. The earnings report indicates significant advancements and strategic initiatives that could notably influence the company's future performance and market position.

Spectral AI, Inc. (MDAI) reported its financial results for the third quarter of 2025, highlighting key metrics such as revenue growth and operational milestones. The company continues to focus on its innovative AI solutions, which are gaining traction in the market. Management expressed optimism about future prospects and strategic initiatives aimed at enhancing shareholder value. The financial results indicate moderate growth and operational progress, which may influence investor sentiment and market positioning.

Spectral AI, Inc. (MDAI) is planning to raise $7.6 million to expedite the development of its DeepView system, which utilizes advanced AI technology for medical imaging. The funding aims to enhance the company's capabilities in delivering innovative solutions in the healthcare sector, particularly in diagnostics and treatment planning. This capital raise is expected to support the acceleration of product development and market entry. The capital raise is a significant strategic move that could enhance product development and market positioning.